Brainstorm Cell Therapeutics Inc (STU:GHD)
€ 2.979 0 (0%) Market Cap: 9.73 Mil Enterprise Value: 7.41 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 36/100

Brainstorm Cell Therapeutics Inc at Noble Financial Emerging Growth Investor Conference Transcript

Feb 17, 2020 / 05:00PM GMT
Release Date Price: €69.9 (-6.80%)
Ralph Kern
Brainstorm Cell Therapeutics Inc. - Chief Operating Officer & Chief Medical Officer

Wonderful, thank you very much. Well, it's a real privilege to be here. I know I'm competing with lunch. So I know that's a tall order. Hopefully, you can last for another half-hour before you have your lunch.

My name is Ralph Kern. I'm the Chief Operating Officer and Chief Medical Officer of Brainstorm Cell Therapeutics. We're a publicly traded company. We trade on NASDAQ as BCLI. This is our disclosure as a publicly traded company.

First of all, I want to give you a bit of an introduction to our company. Some of you already know us. Some of you aren't that familiar with what we do. So I wanted to give you a view from 40,000 feet.

We're a clinical stage biotechnology company. We have the potential to be first-in-class as a company that develops and commercializes a cellular therapy for neurodegenerative disease.

And I'll go through the technology in a few slides to give you a bit more depth. But the basic principle is we're using cells not as a cell replacement

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot